Abbott Sees Metabolic Growth In Knoll: Meridia May Mesh With TriCor
Executive Summary
Abbott sees potential marketing synergies between the triglyceride-lowering agent TriCor (fenofibrate) and Knoll's obesity agent Meridia (sibutramine).
You may also be interested in...
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity